11/12/2025
NEW CLINICAL EVIDENCE
http://www.gyrostim.com/clinical-evidence
Robotic-Assisted Multimodal Neurorehab produces 17× greater therapeutic dose-response and more complete concussion recovery than standard of care alone.
Persistent Post-Concussion Syndrome (PPCS) remains one of the most challenging conditions to treat using traditional neurorehabilitation methods. Standard therapies often fail to fully resolve vestibular, sensorimotor, and cognitive deficits—leading to prolonged recovery, functional limitations, and reduced quality of life.
As an FDA-cleared, FDA-Designated Breakthrough Medical Device, GyroStim delivers multimodal, technology-assisted neurorehabilitation, GyroStim delivers technology-assisted multimodal neurorehabilitation that simultaneously engages vestibular, visual, motor, somatosensory, and cognitive systems—producing faster, more effective, and more complete recovery.
Clinical results show dramatic improvements when GyroStim neurorehabilitation is added to standard of care (SOC) therapies:
· 2× greater improvement in balance and postural control
· 8× greater reduction in symptom severity
· 17× higher therapeutic dose-response per session
By integrating computer-controlled, precisely dosed, high-intensity motion stimulation with interactive visuomotor, visual-vestibular, and cognitive tasks, GyroStim significantly enhances treatment efficiency and accelerates recovery trajectories.
Clinicians report greater patient engagement, faster discharge rates, and superior long-term outcomes—redefining what’s possible in neurorehabilitation.
